IMMUNOSHAPE
Financiado
Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells
IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunot...
IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. To this end, we have set up a training program in a unique academic-industrial environment that will educate young researchers in scientific and practical biomedical glycoscience with the final aim to produce new talent and innovation in the field and improve their career perspectives in both academic and non-academic sectors. The unique combination of 10 academic groups with expertise in automated solid-phase carbohydrate synthesis, microarray based highthroughput screening technology, tumour immunology, structural glycobiology, multivalent systems and medicinal chemistry along with 4 industrial partners active in nanomedicine, immunotherapy, medicinal device development and the fabrication of scientific instrumentation will provide a multidisciplinary and multisectorial training to 15 ESRs in biomedical glycoscience and its industrial applications.
ver más
Duración del proyecto: 47 meses
Fecha Inicio: 2015-01-01
Fecha Fin: 2018-12-31
Fecha Fin: 2018-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-12-31
H2020
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
ASOC CENTRO DE INVESTIGACION COOP EN BIO
No se ha especificado una descripción o un objeto social para esta compañía.
N.D. |
Participante
N.D. |
Participante
N.D. |
Participante
N.D. |
Participante